Parvovirus B19 DNA in plasma pools and plasma derivatives

Vox Sanguinis

Volumn 81, Issue 4, 2001, Pages 228-235

  Schmidt, I ^b   Blumel J ^b   Seitz, H ^b   Willkommen, Hannelore ^a   Lower J ^b  

^a PAUL EHRLICH INSTITUT   (Germany)

^b NONE

Author keywords

B19 DNA detection; Parvovirus B19; Plasma products; Polymerase chain reaction; Virus contamination; Virus safety

Indexed keywords

VIRUS DNA; PLASMA PROTEIN;

ARTICLE; BLOOD SAMPLING; HUMAN; NONHUMAN; PARVOVIRUS; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SAFETY; VIRAL CONTAMINATION; VIRUS DETECTION; BLOOD; BLOOD BANK; DRUG CONTAMINATION; GENETICS; MASS SCREENING; MATERIALS; STANDARD; VIROLOGY;

BLOOD; BLOOD BANKS; BLOOD PROTEINS; CONSUMER PRODUCT SAFETY; DNA, VIRAL; DRUG CONTAMINATION; HUMANS; MANUFACTURED MATERIALS; MASS SCREENING; PARVOVIRUS B19, HUMAN; POLYMERASE CHAIN REACTION;

EID: 0035524555     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.2001.00120.x     Document Type: Article

References (27)

1. Cohen BJ, Buckley MM: The prevalence of antibody to human Parvovirus B19 in England and Wales. J Med Microbiol 1988; 25:151-153
2. Eis-Hübinger AM, Oldenburg J, Brackmann HH, Matz B, Schneweis K: The prevalence of antibody to Parvovirus B19 in haemophiliacs and in the general population. Zbl Bakt 1996; 284:232-240
3. Aubin JT, Defer C, Vidaud M, Montreuil MM, Flan B: Large-scale screening for human Parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionation. Vox Sang 2000; 78:7-12
4. Saldanha J, Minor P: Detection of human Parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol 1996; 93:714-719
5. Eis-Hübinger AM, Sasowski U, Brackmann HH: Parvovirus B19 DNA contamination in coagulation factor VIII products. Thromb Haemost 1999; 81:476-477
6. Hemauer A, von Poblotzki A, Gigler A, Cassinotti P, Siegl G, Wolf H, Modrow S: Sequence variability among different parvovirus B19 isolates. J Gen Virol 1996; 77:1781-1785
7. Mori J, Beattie P, Melton DW, Cohen BJ, Clewley JP: Structure and mapping of the DNA of human Parvovirus B19. J Gen Virol 1987; 68:2797-2806
8. Ferguson M, Walker D, Cohen BJ: Report of a collaborative study to establish the international standard for Parvovirus B19 serum IgG. Biologicals 1997; 25:283-288
9. Cavalli-Sforza L, Lorenz RJ: Biometrie, Grundzüge Biologisch-Medizinischer Statistik. Stuttgart, Gustav Fischer-Verlag, 1974:171-173
10. The European Agency for the Evaluation of Medicinal Products/Committee for Proprietary Medical Products (CPMP) Biotechnology Working Party: Note for Guidance on Virus Validation Studies: the Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses. CPMP/BWP/268/95. 1996 http://www.eudra.org/emea.html
11. Yoto Y, Kudoh T, Haseyama K, Suzuki N, Oda T, Katoh T, Takahashi T, Sekiguchi S: Incidence of human Parvovirus B19 DNA detection in blood donors. Br J Haematol 1995; 91:1017-1018
12. McOmish F, Yap PL, Jordan A, Hart H, Cohen BJ, Simmonds P: Detection of Parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J Clin Microbiol 1993; 31:323-328
13. Ng PK, Dobkin MB: Pasteurization of antihemophilic factor and model virus inactivation studies. Thromb Res 1985; 39:439-447
14. Ozawa K, Young NS: Replication of the B19 parvovirus in human bone marrow cell cultures. Science 1986; 233:883-886
15. Yaegashi N, Shiraishi H, Takeshita T, Nakamura M, Yajima A, Sugamura K: Propagation of human Parvovirus B19 in primary culture of erythroid lineage cells derived from fetal liver. J Virol 1989; 63:2422-2426
16. Takahashi T, Ozawa K, Takahashi K, Asano S, Takaku F: Susceptibilty of human erythropoietic cells to B19 parvovirus in vitro increases with differentiation. Blood 1990; 75:603-610
17. Zakrewska K, Azzi A, Patou G, Morfini M, Rafanelli D, Pattison JR: Human Parvovirus B19 in clotting factor concentrates. B19 DNA detection by the nested polymerase chain reaction. Br J Haematol 1992; 81:407-412
18. Lefrere JJ, Mariotti M, De La Croix I, Lerable J, Thauvin M, Bourouf F, Follea G: Albumin batches and B19 parvovirus DNA. Transfusion 1995; 35:389-391
19. Santagostino E, Mannucci PM, Gringeri A, Azzi A, Morfini M, Musso R, Santoro R, Schiavoni M: Transmission of Parvovirus B19 by coagulation factor concentrates exposed to 100 °C heat lyophilization. Transfusion 1997; 37:517-522
20. Morfini M, Longo G, Rossi Ferrini P, Azzi A, Zakrewska C, Ciappi S, Kolumbian P: Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: the role of human Parvovirus B19. Am J Hematol 1992; 39:149-150
21. Laurian Y, Dussaix E, Parquet A, Chalvon-Demersay A, d'Oiron R, Tchernia G: Transmission of human Parvovirus B19 by plasma derived factor VIII concentrates. Nouv Rev Fr Hematol 1994; 36:449-453
22. Lynch T: Human Parvovirus B19 transmission from SD Plasma. FDA/CBER/Blood Products Advisory Committee, 63rd Meeting, vol. 1. 1999 http://www.fda.gov/ohrms/dockets/ac/99/transcpt/3520tl.rtf
23. Solheim BG, Rollag H, Svennevig JL, Arafa O, Fosse E, Bergerud U: Viral safery of solvent/detergent-treated plasma. Transfusion 2000; 40:84-90
24. Canales MA, Pinilla J, Mateos P, Martinez Zapico R, Alvarez T, Jimenez VM, Quintana M, Villar A, Navarro F, Magallon M: Human Parvovirus B19 antibodies are less frequent among patients treated with Factor IX concentrate inactivated by ultrafiltration: a report from a single Spanish institution. Vox Sang 1998; 74:260-261
25. Azzi A, Ciappi S, Zakrewska K, Morfini M, Mariani G, Manucci PM: Human Parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol 1992; 39:228-230
26. Lefrere JJ, Mariotti M, Thauvin M: B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates. Lancet 1994; 343:211-212
27. Aygören-Pürsün E, Scharrer I: German Kogenate Study group. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant Factor VIII in the treatment of patients with hemophilia A. Thromb Haemost 1997; 78:1352-1356